Percheron Therapeutics Limited

Equities

PER

AU0000317281

Biotechnology & Medical Research

End-of-day quote Australian S.E. Other stock markets 23:00:00 27/05/2024 BST			5-day change	1st Jan Change
0.072 ^AUD	0.00%		-5.26%	+22.03%

05-20	Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	MT
05-06	WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	MT

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

November 14, 2022 at 10:21 pm

Antisense Therapeutics Limited advised that following his significant tenure as the Company's Chief Executive Officer and Managing Director, Mark Diamond has advised that he is retiring as CEO. Mark will continue his responsibilities as CEO until a successor is appointed.

Latest news about Percheron Therapeutics Limited

Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	05-20	MT
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	05-06	MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Dimerix Appoints Nonexecutive Chair	11-20	MT
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	11-15	CI
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	09/10/23	MT
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	25/08/23	CI
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	21/08/23	MT
Antisense Therapeutics Appoints CEO/Managing Director	07/08/23	MT
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	06/08/23	CI
Antisense Therapeutics Limited Announces Management Changes	06/08/23	CI
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	20/07/23	MT
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	27/06/23	CI
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	08/06/23	MT
Antisense Therapeutics Appoints CEO/Managing Director	08/05/23	MT
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	07/05/23	CI
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	07/05/23	CI
Antisense Therapeutics Begins Dosing in Toxicology Study for Muscular Dystrophy Treatment	14/03/23	MT
Antisense Therapeutics Limited Announces the Commencement of Dosing in the Nine-Month Chronic Monkey Toxicology Study of ATL1102	13/03/23	CI
Antisense Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	22/02/23	CI
Antisense Therapeutics Secures Turkish Clearance for Phase 2 Muscular Dystrophy Trial	14/02/23	MT
Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency	13/02/23	CI
Antisense Therapeutics Starts Muscular Dystrophy Animal Study	13/02/23	MT
Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency	12/02/23	CI
Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD	31/01/23	CI

Chart Percheron Therapeutics Limited

Duration

Period

More charts

Company Profile

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Companyâs products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

Sector

Biotechnology & Medical Research

Calendar

27/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Percheron Therapeutics Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.072 AUD

Average target price

0.25 AUD

Spread / Average Target

+247.22%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PERCHERON THERAPEUTICS LIMITED	+22.03%	43.21M
VERTEX PHARMACEUTICALS INCORPORATED	+9.83%	118B
REGENERON PHARMACEUTICALS, INC.	+10.80%	106B
BIONTECH SE	-10.84%	23.4B
ARGENX SE	-1.69%	22.1B
GENMAB A/S	-10.23%	18.34B
WUXI APPTEC CO., LTD.	-41.92%	16.59B
BEIGENE, LTD.	-15.11%	15.97B
NEUROCRINE BIOSCIENCES, INC.	+6.62%	14.03B
SAREPTA THERAPEUTICS, INC.	+17.53%	11.67B

Bio Therapeutic Drugs